Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Liraglutide

A historical comparator for the evolution of GLP-1 medicines and the transition from diabetes into weight management.

Conceptual three-dimensional molecular signature for Liraglutide; not an exact chemical structure.
GLP-1 receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved in specific products and indications

MHRA / UK LICENCE

UK authorised in specific products and indications

NICE STATUS

NICE TA664 recommends liraglutide for a defined obesity pathway

NHS ACCESS

Specialist NHS access exists within relevant criteria

PRIVATE LAWFUL USE CONTEXT

Lawful private prescribing is product, indication and prescriber specific

EVIDENCE MATURITY

Long standing controlled evidence and post marketing use

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

High

PROFESSIONAL RELEVANCE

Benchmark lifecycle evidence, indication expansion and policy adaptation against newer metabolic peptides.

Product, formulation and indication

Saxenda

UK · Injection

Weight management

Victoza

UK · Injection

Type 2 diabetes

Status history

Production baseline verification recorded.

Established FDA approved peptide medicine

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.